← Back to The Daily Signal
Peptides

Retatrutide Roughly Doubled Ozempic's Weight Loss in Its First Head to Head Trial. The Data Are Still Lilly's Own

Retatrutide works on three hormone receptors where semaglutide works on one, and every trial so far has suggested that matters for weight. Until now, though, it had only been compared with placebo. This is the first time it has faced a drug millions of people already take.

Written by Sama Alabed · November 19, 2026

The short version

The trial

A needle being inserted into a pinched fold of skin for a subcutaneous injection

A subcutaneous injection, the way weekly GLP-1 drugs are given.

British Columbia Institute of Technology (BCIT)CC BY 4.0

Illustrative. A training demonstration with an insulin needle, not retatrutide or semaglutide.

TRANSCEND-T2D-2 enrolled 1,298 adults with type 2 diabetes who were already taking metformin, with or without an SGLT-2 inhibitor. They were assigned to retatrutide at 9 mg or 12 mg, or to semaglutide at 2 mg, the dose used in Ozempic, for 80 weeks. Retatrutide acts on GLP-1, GIP and glucagon receptors.

Participants and doctors knew which drug was being given. That design, called open label, makes comparisons less reliable, especially for outcomes that depend on behavior, like weight.

The results Lilly reported

A1C, the long term blood sugar measure, fell by 2.2 points on both retatrutide doses and by 1.8 points on semaglutide. Body weight fell by 19.5 percent on 9 mg and 20.9 percent on 12 mg, against 9.4 percent on semaglutide, a little over twice as much. These figures use the efficacy estimand, which counts people who stayed on their assigned treatment.

19.5%

Retatrutide 9 mg

Weight lost at 80 weeks.

20.9%

Retatrutide 12 mg

Weight lost at 80 weeks.

9.4%

Semaglutide 2 mg

Weight lost at 80 weeks.

1,298 adults with type 2 diabetes, open label, company reported topline results, not yet peer reviewed.

More people stopped retatrutide because of side effects: 4.8 percent on 9 mg and 7.9 percent on 12 mg, against 2.7 percent on semaglutide. Dysesthesia, an abnormal or unpleasant skin sensation that has appeared in earlier retatrutide trials, was reported in 4.8 and 6.5 percent, against 2.7 percent.

How much weight to put on this

The gap in weight loss is large enough that open label bias alone is unlikely to explain all of it. Still, these are topline numbers in a press release. The full results, with confidence intervals, dropout handling and safety details, have not been published or reviewed.

these are topline numbers in a press release

Retatrutide is not approved anywhere, and products sold online under its name are not the drug tested here.

Honest caveat

Company reported topline results from an open label trial, not yet peer reviewed. We read trade coverage of Lilly's announcement because Lilly's own page did not load. The trial included only people with type 2 diabetes, who usually lose less weight on these drugs than people without diabetes. Retatrutide is investigational.

What this means for you

If you take semaglutide, nothing here changes your treatment today; retatrutide is not available outside trials. It does suggest that the next generation of drugs may offer more weight loss for people who need it, at the cost of more side effects.

If you see retatrutide for sale online, it is not an approved medicine and its contents are unknown. That is one of the clearest safety lines in this whole area.

Primary sources

  1. HCPLive, October 2026: TRANSCEND-T2D-2 topline results reported by Eli Lilly, trial NCT06260722

Common questions

How much weight did people lose on retatrutide?

19.5 percent on 9 mg and 20.9 percent on 12 mg over 80 weeks, against 9.4 percent on semaglutide 2 mg, according to Lilly's topline results in adults with type 2 diabetes.

Is retatrutide approved?

No. It is investigational. Products sold online as retatrutide are not the drug tested in Lilly's trials.

Why does open label matter?

When participants and doctors know which drug is given, expectations can affect behavior and reporting. It makes head to head comparisons less reliable than a blinded trial.

Continue readingPeptidesRoche's New GLP1 Shot Enicepatide Just Posted 15.5% Weight Loss in a Real TrialRoche's enicepatide, a new GLP1 and GIP drug from its Carmot acquisition, hit 15.5% weight loss and got 62% of trial patients to normal blood sugar in a Phase 2 trial, still company reported data.Read the story
RetatrutideSemaglutideGLP-1Weight LossType 2 Diabetes

#Retatrutide#Semaglutide#GLP1#WeightLoss#Diabetes

Stay Curious.

Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.